You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新鋭醫藥(06108.HK):獨立董事委員會對收購事項的調查仍在進行
格隆匯 11-01 21:00

格隆匯11月1日丨新鋭醫藥(06108.HK)公佈,致同諮詢服務有限公司已獲委任為獨立董事委員會的獨立調查機構以協助調查。獨立調查機構正在編制其獨立調查報告。直至本公告日期,獨立董事委員會對有關該等收購事項的事宜的調查仍在進行。鑑於各種情況,該公司無法於當前階段制定任何訂有明確時限的實際可行的恢復買賣計劃。該公司將繼續尋求法律意見以儘快恢復股份的買賣。

公司稱,儘管股份暫停買賣,該集團一直照常開展業務及繼續專注於中國從事醫藥產品分銷及貿易業務以及提供營銷及推廣服務。董事會欣然通知股東及有意投資者,該產品的製造商近期知會該集團,其已完成該產品(1.0克)製造程序的徹底檢測及審查,且已自2019年9月起恢復該產品(1.0克)的生產及銷售。於本公告日期,該產品(0.5克)的生產及銷售仍然暫停。該集團預期過去三個季度該產品(包括1.0克及0.5克)的生產及銷售短暫暫停將對該集團本年度收益造成不利影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account